Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

NCT03092323 is registered in ClinicalTrials.gov with Sarcoma Alliance for Research through Collaboration as lead sponsor.

NCT NCT03092323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03092323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 19, 2017
Completion date
September 1, 2028
Enrollment
126 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma of the extremity